UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

被引：4
|
作者：
Peeters, Sofia L. J. [1 ,2 ]
Deenen, Maarten J. [1 ,2 ]
Thijs, Anna M. J. [3 ]
Hulshof, Emma C. [1 ,2 ]
Mathijssen, Ron H. J. [4 ]
Gelderblom, Hans [5 ]
Guchelaar, Henk-Jan [2 ]
Swen, Jesse J. [2 ]
机构：
[1] Catharina Hosp, Dept Clin Pharm, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Catharina Hosp, Dept Med Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[4] Erasmus MC, Dept Med Oncol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 09期
关键词：
irinotecan; personalized medicine; PGx; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment; UGT1A1; PHARMACOGENETICS; IMPLEMENTATION; NEUTROPENIA; TOXICITY; THERAPY; RISK;
D O I：
10.2217/pgs-2023-0096
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care. © 2023 Future Medicine Ltd.
引用
收藏
页码：435 / 439
页数：5
相关论文
共 50 条
  • [1] Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
    Hulshof, Emma C.
    de With, Mirjam
    de Man, Femke M.
    Creemers, Geert-Jan
    Deiman, Birgit A. L. M.
    Swen, Jesse J.
    Houterman, Saskia
    Koolen, Stijn L. W.
    Laven, Marjan
    Luelmo, Saskia
    van Schaik, Ron H. N.
    Guchelaar, Henk-jan
    Mathijssen, Ron H. J.
    Gelderblom, Hans
    Deenen, Maarten J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
    Hulshof, Emma C.
    de With, Mirjam
    de Man, Femke M.
    Creemers, Geert-Jan
    Deiman, Birgit A. L. M.
    Swen, Jesse J.
    Houterman, Saskia
    Koolen, Stijn L. W.
    Bins, Sander
    Thijs, Anna M. J.
    Laven, Marjan M. J.
    Hovels, Anke M.
    Luelmo, Saskia A. C.
    Houtsma, Danny
    Shulman, Katerina
    McLeod, Howard L.
    van Schaik, Ron H. N.
    Guchelaar, Henk-Jan
    Mathijssen, Ron H. J.
    Gelderblom, Hans
    Deenen, Maarten J.
    EUROPEAN JOURNAL OF CANCER, 2022, 162 : 148 - 157
  • [3] Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
    Kong, Lingti
    Rong, Li
    Wang, Muhua
    EUROPEAN JOURNAL OF CANCER, 2022, 170 : 194 - 195
  • [4] Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
    Hulshof, Emma C.
    de With, Mirjam
    Creemers, Geert-Jan
    Guchelaar, Henk-Jan
    Mathijssen, Ron HJ.
    Gelderblom, Hans
    Deenen, Maarten J.
    EUROPEAN JOURNAL OF CANCER, 2022, 172 : 231 - 233
  • [5] UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
    Matthew P. Goetz
    Heidi A. McKean
    Joel M. Reid
    Sumithra J. Mandrekar
    Angelina D. Tan
    Mary A. Kuffel
    Stephanie L. Safgren
    Renee M. McGovern
    Richard M. Goldberg
    Axel A. Grothey
    Robert McWilliams
    Charles Erlichman
    Matthew M. Ames
    Investigational New Drugs, 2013, 31 : 1559 - 1567
  • [6] UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
    Goetz, Matthew P.
    McKean, Heidi A.
    Reid, Joel M.
    Mandrekar, Sumithra J.
    Tan, Angelina D.
    Kuffel, Mary A.
    Safgren, Stephanie L.
    McGovern, Renee M.
    Goldberg, Richard M.
    Grothey, Axel A.
    McWilliams, Robert
    Erlichman, Charles
    Ames, Matthew M.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1559 - 1567
  • [7] Towards UGT1A1 guided irinotecan dosing
    Hicks, J. Kevin
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 (09) : 980 - 981
  • [8] Towards UGT1A1 guided irinotecan dosing
    J. Kevin Hicks
    European Journal of Human Genetics, 2023, 31 : 980 - 981
  • [9] Evaluation of severe neutropenia and diarrhea in Asian cancer patients receiving UGT1A1 genotype-guided irinotecan dosing.
    Sutiman, Natalia
    Ramasamy, Saminathan
    Ng, Chau Hsien Matthew
    Choo, SuPin
    Wenrui, Rachel Lim
    Ling, Clarinda Chua Wei
    Kuang, John Chia Whay
    Tan, Iain B.
    Chowbay, Balram
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).
    Sharma, Manish
    Toffoli, Giuseppe
    Buonadonna, Angela
    Marangon, Elena
    Polite, Blase N.
    Frustaci, Sergio
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345